ACSL6
Long-chain-fatty-acid--CoA ligase 6
Also known as: ACS2, ACSL6_HUMAN, FACL6, KIAA0837, LACS2, LACS5
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- Q9UKU0
- Gene
- ACSL6
- Ensembl
- ENSG00000164398
- Chromosome
- 5
- Canonical length
- 697 aa
- Protein class
- Disease related genes, Enzymes, Metabolic proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins
OverviewNCBI Gene
The protein encoded by this gene catalyzes the formation of acyl-CoA from fatty acids, ATP, and CoA, using magnesium as a cofactor. The encoded protein plays a major role in fatty acid metabolism in the brain. Translocations with the ETV6 gene are causes of myelodysplastic syndrome with basophilia, acute myelogenous leukemia with eosinophilia, and acute eosinophilic leukemia. Several transcript variants encoding different isoforms have been found for this gene.[provided by RefSeq, Apr 2011]
Canonical amino-acid sequenceUniProt
697 residues, UniProt reviewed canonical sequence.
>Q9UKU0|ACSL6
1 MQTQEILRIL RLPELGDLGQ FFRSLSATTL VSMGALAAIL AYWFTHRPKA LQPPCNLLMQ
61 SEEVEDSGGA RRSVIGSGPQ LLTHYYDDAR TMYQVFRRGL SISGNGPCLG FRKPKQPYQW
121 LSYQEVADRA EFLGSGLLQH NCKACTDQFI GVFAQNRPEW IIVELACYTY SMVVVPLYDT
181 LGPGAIRYII NTADISTVIV DKPQKAVLLL EHVERKETPG LKLIILMDPF EEALKERGQK
241 CGVVIKSMQA VEDCGQENHQ APVPPQPDDL SIVCFTSGTT GNPKGAMLTH GNVVADFSGF
301 LKVTEKVIFP RQDDVLISFL PLAHMFERVI QSVVYCHGGR VGFFQGDIRL LSDDMKALCP
361 TIFPVVPRLL NRMYDKIFSQ ANTPLKRWLL EFAAKRKQAE VRSGIIRNDS IWDELFFNKI
421 QASLGGCVRM IVTGAAPASP TVLGFLRAAL GCQVYEGYGQ TECTAGCTFT TPGDWTSGHV
481 GAPLPCNHIK LVDVEELNYW ACKGEGEICV RGPNVFKGYL KDPDRTKEAL DSDGWLHTGD
541 IGKWLPAGTL KIIDRKKHIF KLAQGEYVAP EKIENIYIRS QPVAQIYVHG DSLKAFLVGI
601 VVPDPEVMPS WAQKRGIEGT YADLCTNKDL KKAILEDMVR LGKESGLHSF EQVKAIHIHS
661 DMFSVQNGLL TPTLKAKRPE LREYFKKQIE ELYSISMLocalizationUniProt · AlphaFold · HPA
Whether an antibody against ACSL6 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Other membrane
- Secreted
- No
- Transmembrane segments
- 1
- Mean surface accessibility (rSASA)
- 0.23
- Highest tissue expression
- 42 nTPM
Expression across tissuesHPA
Tissue
- retina: 42 nTPM
- cerebral cortex: 30 nTPM
- cerebellum: 28 nTPM
- bone marrow: 21 nTPM
- amygdala: 20 nTPM
- testis: 19 nTPM
Single-cell type
- late primary spermatocytes: 5.3 nCPM
- astrocytes: 4.2 nCPM
- bergmann glia: 3.5 nCPM
- rod photoreceptor cells: 1.6 nCPM
- early spermatids: 1.5 nCPM
- retinal amacrine cells: 1.4 nCPM
Immune cell
- memory CD8 T-cell: 1.6 nTPM
- MAIT T-cell: 1.1 nTPM
- naive CD4 T-cell: 1.1 nTPM
- memory CD4 T-cell: 0.7 nTPM
- naive CD8 T-cell: 0.5 nTPM
- gdT-cell: 0.4 nTPM
Brain region
- cerebral cortex: 85 nTPM
- cerebellum: 75 nTPM
- thalamus: 72 nTPM
- medulla oblongata: 67 nTPM
- pons: 59 nTPM
- hippocampal formation: 58 nTPM
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 0.48
- gnomAD pLI
- 0
- gnomAD missense Z
- 1.76
- DepMap mean gene effect
- -0.07
- DepMap dependency class
- selective
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 3% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
- acyl-CoA metabolic process
- long-chain fatty acid metabolic process
- long-chain fatty-acyl-CoA biosynthetic process
- neuroblast proliferation
- very long-chain fatty acid metabolic process
Molecular functions
- arachidonate-CoA ligase activity
- ATP binding
- enzyme binding
- long-chain fatty acid-CoA ligase activity
- protein homodimerization activity
Cellular components
Protein domainsUniProt · Pfam · InterPro
KeywordsUniProt
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads ACSL6 as an antibody target. Whether an autoantibody or antibody against ACSL6 could matter depends on whether native ACSL6 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
ACSL6 is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.
Annotation status
The present source text does not explicitly label ACSL6 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...